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Abstract
Background: Cognitive and motor-performance decline with age and the process is accelerated by decline in
general health. In this study, we aimed to estimate the effects of COPD and HB levels on cognitive and motor
performance in the general older population and assess potential interaction.
Methods: The English Longitudinal Study of Aging is a population-based cohort study including measurements of
lung-function and HB levels together with cognitive and motor performance testing. Data were collected from
5709 participants including three measurement time over eight years. COPD was defined using lung-function-
parameters and clinical symptoms. HB was assessed continuously and low HB was defined using clinical anemia
cutoffs. Linear mixed-effects regression models were used to quantify the associations of COPD and HB with
outcome measures, both individually and in combination.
Results: Participants with both low HB and COPD demonstrated worse motor performance compared to
individuals with only one exposure, resulting in up to 1 s (95%CI, 0.04–1.8) longer time needed to complete the five
times sit to stand task than what would be expected based on purely additive effects. Additionally in individuals
with COPD, the time to complete the motor-performance task per unit decrease in continuous HB levels was
longer than in participants without COPD after full adjustment for confounding (up to 1.38 s/unit HB level, 95% CI:
0.65–2.11).
Conclusion: In persons with COPD low HB levels may contribute to low motor-performance in a supra additive
fashion. Further studies should re-evaluate whether earlier treatment of lower HB in these individuals might be
beneficial.
Keywords: Chronic obstructive pulmonary disease, Anemia, Motor function, Cognitive function, Interaction
Background
With increasing age, both cognitive and motor-
performance begin to slowly decline [1, 2]. Both func-
tions may influence each other; cognitive impairment
has been shown to be associated with an increase in the
number of falls among older people, and successfully
performing motor tasks, e.g. the five times sit-to-stand
test, was found to be inversely associated with cognitive
impairment [3, 4].
Next to interdependency, decline of both motor and
cognitive function may be further enhanced by certain
conditions common in the older population, such as
COPD and low HB (hemoglobin) level [5–8]. When in-
dividuals suffer from both low HB level and COPD,
existing evidence indicates that outcomes such as the
development of respiratory failure and mortality in crit-
ically ill hospitalized patients but also in the general
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population may occur more frequently than in persons
who suffer only from one condition [9] [10]. Both factors
have previously been shown to independently reduce exer-
cise capability and increase feelings of dyspnea [11], while
persons suffering from both conditions reported lower
quality of life compared to persons with COPD alone [12].
Anemia caused by iron depletion and anemia of chronic
disease that occurs in patients with acute or chronic im-
mune activation represent the two most common causes
for anaemia [13, 14]. However, especially in an older
population also renal insufficiency or vitamin d deficiency
may relevant causal factors for low HB levels. Potentially
partly associated with chronic inflammation, low HB levels
have been reported to occur more frequently among per-
sons with COPD with a prevalence between 10 and 30%
in COPD patients and approximately 6% in the general
older population [11, 12, 15, 16]. On the other hand, HB
levels have been reported to increase by an erythropoietin
mediated mechanism that to some degree compensates
for the oxygen deprivation characteristic of chronic dis-
eases such as COPD [6].
To our knowledge, no studies thus far have examined
in detail how low HB levels alone or in combination
with COPD may be associated with cognitive and motor
performance in the general older population. In the
present study, we aimed to quantify effect estimates for
both conditions separately as well as probe whether
supra-additive biological effects due to interaction on
these performance measures might be present in the
general older population.
Methods
The ELSA study, main dataset
The ELSA (English Longitudinal Study on Ageing) study
is a prospective cohort study funded by a consortium of
UK-Government departments and the National Institute
of Aging in the UK to study the socio-economic and
health implications of aging. It collects longitudinal,
multidisciplinary data from a representative sample of
the English general population aged 50 and older living
at private residential addresses [17, 18]. After the first
wave of recruitment, 12,099 participants were enrolled
and household interviews were conducted. To maintain
the size and representativeness of the panel over time,
additional study participants aged 50–55 were recruited
during waves 3, 4, and 6. In the present study, we used
interview data collected every year in combination with
the nursing data subset. In this subset of participants,
medical information was collected in waves 2, 4 and 6
over a period of 8 years. During wave 2, nursing data
were obtained for 7666 participants for the first time
and blood samples were collected from 5841 of those
participants (Fig. 1).
We excluded participants whose data on the status of
lung function and clinical symptoms needed for COPD
definition did not match. This means participants who
did not report chronic clinical symptoms of COPD (dys-
pnoea, phlegm, wheezing) but had lung function mea-
surements indicating impairment were excluded. Further
excluded were participants fulfilling the definition of
‘healthy’ according to the lung function data but who re-
ported chronic clinical symptoms for COPD (also see
measurement section) [19]. Finally, participants with
missing data on measurements (15% missing) included
in main analysis model (M1) were excluded.
In total, the number of participants with complete
household and nursing data that could be used for the
main analysis included 2825 participants for wave 2 only
(Fig. 1) and 5709 across all waves (age range 50 to 99;
collapsed to 99 at 90+ to protect anonymity). From these
5709 participants, a total of 8351 measurements were
collected over a maximum of three measurement time
points (Fig. 1).
Measurements
Measurements for the lung function parameters, HB
levels, grip strength, blood pressure, motor performance,
HBA1C and cholesterol level, used in our analyses were
assessed in follow up nurse visits (nursing datasets) wave
2, 4 and 6. Data on clinical symptoms of COPD, age
(starting at 50 and older), cognitive performance, alcohol
consumption, depression, prior stroke and myocardial
infarction (MI) were included as part of the main dataset
and measured each wave. The information about prior
stroke or MI, clinical symptoms of COPD and alcohol
consumption were self-reported during each wave.
Number of test reputations was generated by counting
the number of waves that the persons continued to par-
ticipate in the study after baseline assessments.
Exposures
We defined COPD based on lung function parameters
according to GOLD criteria supplemented with informa-
tion on clinical symptoms. Categorization into healthy
(FEV1/FVC > 69% and expected FEV1 > 79), mild (FEV1/
FVC < 70%), moderate (FEV1/FVC < 70% and expected
FEV1:50–79%), severe (FEV1/FVC < 70% and expected
FEV1 30–49%),or very severe (FEV1/FVC < 70% and ex-
pected FEV1 < 30) COPD was based on clinical cutoffs
based on the severity of airflow restriction as measured
by the proportion of expected forced expiratory volume
(FEV1) divided by forced vital capacity (FVC) and ex-
pected FEV1 [20, 21] (Additional file 1: Table S1). Spir-
ometry measures were obtained without bronchodilator
treatment.
Low HB levels were defined using current clinical cut-
off levels for anemia (< 12.0 g/dl for women, < 13.5 g/dl
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for men) [22]. We also assessed HB levels as a mean-
centered continuous variable.
Outcomes
We operationalized functional outcome using both mea-
sures of cognitive and motor performance. Cognitive
performance (number of words memorized) was mea-
sured using delayed words recall with ten words [23].
Motor function (time to complete chair rise) was
assessed by measuring the time needed to complete five
chair raises. To allow for comparative analysis in the ta-
bles and figures, both outcome variables were standard-
ized by dividing mean-centered values by the common
standard deviation for each measure. Through this trans-
formation, we could compare the effect estimates for
both outcome variables on a common scale. All esti-
mated effects are presented as standardized effect sizes
(Cohen’s d). A definition of the supplementary outcomes
immediate words recall and balance was included in the
supplementary section.
Confounding variables
We identified the following variables as potential sources
of confounding based on a priori knowledge: sex, age,
blood pressure, myocardial infarction (MI), stroke, dia-
betes, total cholesterol, alcohol, smoking, depression and
grip strength. Further details on the definition and cate-
gorizations used can be found in the supplementary
section.
Statistical analysis
The analysis dataset was generated from the ELSA data
repository [17], accessed in May 2018 using SPSS
Fig. 1 Flowchart. Data used in main model 1 were based on participants for whom blood sample measurements from nursing datasets were
available and who also had complete and consistent data on chronic obstructive pulmonary disease (COPD) as well as other variables included in
model M1. To maintain the size and representativeness of the panel during waves 3, 4, and 6 additional study participants were recruited. The
numbers given in the boxed therefore represent the sum of participants measured for the first time and participants who were already measured
at a previous wave. The numbers of participants who continued with complete model 1 data from a previous to next waves are indicated above
the arrows connecting the boxes from wave 2 to 4 (w2, w4) and 4 to 6 and for the total number of cases including all COPD subgroups also
those that continue from w2 directly to w6. Updated values were used at each measurement time point. The dataset includes 8351
measurements collected over the three waves from 5709 participants
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version 22. Subsequent analyses were performed using
Stata IC 14.
Baseline characteristics were stratified by COPD func-
tion and are reported as median values and interquartile
range limits for continuous variables, or absolute num-
bers and percentages for categorical variables.
To assess the relation between COPD categories and
low as well as continuous HB levels (using continuous
values measured in mg/dl) on functional outcomes
(namely number of words memorized and time to
complete chair rises), we used linear mixed-effects re-
gression models. These included individual participants
as the level 2 units (random intercept model) and the re-
peated measurements per individual as the level 1 units.
If available, updated variables were incorporated at each
new measurement time point. We assessed the relative
effects due to (biological) interaction by combining the
two categorical exposure variables, COPD and low HB,
in six combinations in order to assess whether the com-
bination of both medical conditions results in supra-
additive effects with respect to the functional outcomes.
The healthy, mild and moderate, as well as the severe
and very severe categories of COPD were collapsed into
three broader categories of COPD-severity (healthy,
mild-to-moderate, and severe-to-very severe, each fur-
ther divided in a group with and a group without low
HB).
In a second analysis a product term between COPD cat-
egories and continuous HB levels was introduced to quan-
tify the difference in the effect size of the association
between continuous HB levels (in mg/dl) and functional
outcome measures in five (healthy, mild, moderate, severe
and very severe) different COPD categories.
We used two models to adjust for potential sources of
confounding. The first model 1 (M1) included sex and
age as well as the number of test repetitions in order to
account for the practice effects associated with a better
knowledge of the task. In a second fully adjusted model
(M2), additional adjustment was made for blood pres-
sure, myocardial infarction (MI), stroke, diabetes, total
cholesterol, alcohol, and smoking. Here we also included
grip strength and depression according to the CES-D de-
pression scale as markers in M2 to account for the fact
that a general decrease in physical or psychological well-
being may have also been a source of confounding. We
acknowledge grip strength and depression may be inter-
mediates on the causal path, and comment on this in
our discussion.
Handling of missing data
In the fully adjusted analysis, missing data on some of the
covariates impacted the number of individuals who could
be included in the complete-case analyses. For this reason,
missing values for additional confounder variables were
imputed based on the complete M1 dataset and available
values for M2. Multiple imputation by chained equations
(MICE) [24] was conducted to create 10 datasets in which
estimates for missing data in the variables alcohol, choles-
terol, grip-strength, blood pressure depression, smoking
and HBA1C level were calculated using the outcome vari-
ables of time needed to complete five chair raises and
words recalled, as well as variables without missing values
used in M1 namely lung function, HB, age, sex and the
number of test repetitions and the non-missing data of
the covariates used in M2.
Sensitivity analysis
Multiple sensitivity analyses were conducted to assess
robustness of our findings. This included (a) a complete
case analysis of model M2, (b) an analysis incorporating
cross-sectional and longitudinal analytical weights for
representativeness, and (c) an analysis using a broader
more inclusive definition of COPD. Further details on
the sensitivity analysis can be found in the supplemen-
tary methods section.
Results
The final dataset used in model M1 included 8351 mea-
surements collected over the three waves from 5709 partici-
pants (Fig. 1). Baseline data (meaning first measurements
available from each participant, whenever entering the
study) from 5709 participants are shown in Table 1.
Model 2 included additional confounders resulting in
3723 individuals without and 1986 individuals with miss-
ing data on additional confounders. The main results
presented in Tables 2 and 3 use the dataset with imput-
ation of missing values for additional confounding vari-
ables in model M2.
When looking at baseline data 780 (13.7%) of all par-
ticipants had some level of COPD at baseline; 616
(10.8%) were mildly or moderately affected (COPD
groups 1 + 2) and 164 (2.9%) were affected severely or
very severely (COPD groups 3 + 4). Low HB levels
(anemia) was present in 7.3% of the healthy participants,
in 13.3% of those with mild COPD, in 12.1% of those
with moderate COPD, in 11.5% of those with severe and
in 4.2% of the participants with very severe COPD. Me-
dian HB levels, however, did not differ much between
persons with and without COPD (Table 1) but were
slightly higher among those with very severe COPD
(group 5). As shown in Table 1, among those with
COPD, the proportion of males was higher, and the pro-
portion of current smokers was much higher compared
to those without COPD. In line with previous findings
[25] also depression rates were higher in persons with
COPD (Table 1). Furthermore the rates of prior stroke
and myocardial infarction (MI) were higher among
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participants with COPD, and those with COPD were
more frequently hypertensive.
In an unadjusted crude comparison of baseline mea-
sures, the median time to complete five chair rises was
higher in individuals with higher severity of COPD,
while the median number of words memorized did not
differ substantially upon comparing persons with and
without COPD (Table 1). Compared to participants with
normal HB levels, the median number of words
memorized was lower and the time to complete five
chair rises was longer among participants with low HB
levels (Additional file 1: Table S2). Correction for analyt-
ical weights did not fundamentally alter these crude re-
sults (Additional file 1: Table S3).
Finally, in a post hoc analysis assessing unadjusted
strata of COPD categories in combination with low ver-
sus normal HB levels, CRP-levels were found to be high-
est among those with severe and very severe COPD and
Table 1 Participant baseline characteristics (n = 5709 cases)
COPD Status Healthy, n = 4929 Mild n = 246 Moderate n = 370 Severe n = 124 Very severe n = 40
Age (years) median [IQR] 61 [56–69] 67 [60–75] 67 [61–73] 68 [63–73] 64 [59–69]
Male sex % (n) 45% (2224) 52% (129) 47% (175) 46% (57) 60% (24)
HB (g/dl) median [IQR] 14.20 [13.40–15.10] 14.20 [13.30–15.10] 14.20 [13.40–15.03] 14.20 [13.40–15.20] 14.55 [13.73–15.40]
Diabetes (as % glycated HB > 6.5) in % (n) 5% (224) 7% (16) 7% (26) 11%(14) 3% (1)
Total cholesterol (mmol/l) median [IQR] 5.80 [5.10–6.60] 5.50[4.80–6.40] 5.50 [4.70–6.30] 5.70 [4.80–6.68] 5.75 [5.00–6.58]
Depression (CES-D scale> = 4) in % (n) 9% (457) 17% (43) 20% (73) 21% (26) 23% (9)
Grip (kg) median [IQR]) 29.67 [23.33–40.33] 28.17 [20.67–38.91] 27.67 [21.67–36.00] 26.67 [21.67–32.67] 28.00 [22.75–38.17]
Self-reported prior stroke (yes/no) in % (n) 2% (75) 6% (14) 4% (14) 4% (5) 5% (2)
Self-reported prior MI (yes/no) in% (n) 2% (103) 5% (11) 6% (24) 4% (5) 10% (4)
Self-reported current Smoking in % (n) 7% (405) 15% (37) 30% (109) 36% (44) 33% (13)
Self-reported Alcohol (frequency of days
drinking/week) median [IQR]
3 [2–4] * 3 [1–4] * 3 [1–4] * 3 [1–4] * 3[1–4] *
HypertensionA in % (n) 23%* 29% * 34%* 36% * 25% *
Number Words memorized (n) median [IQR] 5.0 [4.0–6.0] 4.50 [3.0–6.0] 5.0 [3.0–6.0] 5.0 [3.0–6.0] 5.0 [4.0–6.0]
Time needed to complete five chair rises
(seconds) median [IQR]
10.12 [8.26–12.31] 11.60 [9.06–13.86] 11.62 [9.28–14.57] 13.18 [10.62–15.75] 12.08 [10.15–15.60]
Values represent measured data at baseline without any centering or standardization performed
Abbreviations: MI myocardial infarction, IQR interquartile range, HB hemoglobin, COPD chronic obstructive pulmonary disease
* > 5% of data points missing in the following variables: alcohol in healthy (n = 3312), mild COPD (n = 136), moderate (n = 208), severe (n = 73), very severe
(n = 23) and for hypertension in healthy (1075/4629, 23%) mild COPD (66/224, 29%), moderate COPD(116/337,34%),severe COPD (38/107, 36%) and very
severe COPD(9/36,25%)
Amean systolic at least > 140 or diastolic > 90 or intake of antihypertensive medication in % (n)
Table 2 Effects of the combination of low HB and COPD on cognitive and motor outcomes; standardized effect sizes and 95%CI
COPD category +low HB Time to complete chaira rise Number of Words memorized a
M1b M2c M1a M2c
NO COPD
N = 7305d
NO N = 6770d 1 (ref) 1 (ref) 1 (ref) 1 (ref)
YES = 535d 0.14 (0.06 to 0.22) 0.09 (0.02 to 0.17) −0.14 (− 0.22 to − 0.06) -0.1 (− 0.18 to 0.02)
Mild and moderate COPD




0.22 (0.15 to 0.29) 0.15 (0.08 to 0.22) − 0.14 (− 0.21 to − 0.07) −0.09 (− 0.17 to 0.01)
YES
N = 106d
0.62 (0.44 to 0.8) 0.5 (0.33 to 0.68) −0.1 (− 0.28 to 0.08) −0.01 (− 0.19 to 0.17)
Severe and very severe




0.53 (0.3 to 0.66) 0.41 (0.28 to 0.55) −0.16 (− 0.3 to − 0.02) −0.08 (− 0.22 to 0.06)
YES
n = 20d
0.92 (0.53 to 1.3) 0.8 (0.42 to 1.18) −0.27 (− 0.66 to 0.12) − 0.17 (− 0.55 to 0.22)
amodeled as the decrease per SD (SD−1) in words memorized and time to complete chair raises
badjustment model 1: sex and age, number of test repetitions; N = 8351 measurements; 5709 persons
cmodel 2 additionally adjusts for blood pressure, myocardial infarction (MI), stroke, diabetes, total cholesterol, alcohol, depression grip strength and smoking,
imputed from complete data for M1 and available values for M2
dn =measurements
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low HB with an average of 14 mg/l compared to 7.2 mg/l
in persons with only severe and very severe COPD and
4.4 mg/l in persons with only low HB.
Individual associations between COPD and low HB on
motor and cognitive performance
Having low HB levels was associated with a 0.54 s
(95% CI: 0.24–0.84) longer time to complete the
motor performance task in model M1. The standard-
ized effect size for low HB level was 0.14 (95% CI:
0.06 to 0.22; Table 2).
In participants with normal HB levels, the presence of
mild or moderate COPD was associated with a 0.85 s
(95% CI: 0.57–1.14) longer time (standardized effect size:
0.22, 95% CI: 0.15–0.29) to complete the motor per-
formance task in model M1. Those with normal HB
levels and severe or very severe COPD needed 2.05 s
(95% CI: 1.51–2.58) longer to complete five chair raises
(standardized effect size: 0.53 (95% CI: 0.3–0.66)). Asso-
ciations were attenuated after full adjustment for con-
founding in M2 (with a standardized effect size of 0.15
(95% CI: 0.08 to 0.22) for mild and moderate and 0.41
(95% CI: 0.28 to 0.55) for severe and very severe COPD).
Similar results were obtained in complete case analyses
without imputation (Additional file 1: Table S4).
When looking at cognitive performance as measured
by the number of words memorized, participants with
low HB performed worse: on average − 0.27 (95% CI:-
0.42 to − 0.11) fewer words memorized in model M1
(standardized effect size: -0.14 (95% CI: − 0.20 to − 0.06).
However, the absolute values of the associations were
much smaller after inclusion of additional covariates in
M2. Similarly, the effects on the number of words
memorized that were observed for mild and moderate
COPD (− 0.14(95% CI: − 0.21 to − 0.07)) and for severe
and very severe COPD (− 0.16 (95% CI: − 0.3 to − 0.02))
without anemia in model 1 were much smaller after in-
clusion of additional covariates in model 2.
Combinations of COPD and low HB levels and their
association with motor and cognitive performance
The combination of low HB and the presence of COPD
was found to be associated with a lower motor perform-
ance than expected based on the purely additive bases. For
the chair raises, an additional 1.02 (95% CI: 0.43–1.61)
seconds above what would be expected on an additive
basis in model M1 were needed for individuals with mild
or moderate COPD and an additional 0.98 s (95% CI:
0.15–1.82) for severe and very severe COPD. The corre-
sponding standardized estimates were 0.26 (95%CI 0.11–
0.41) and 0.25 (95% CI: 0.04–0.56) (Table 2).
Also after full confounding adjustment, supra-additive
effects for the association of COPD and low HB with
motor-performance were observed in M2. In partici-
pants with low HB, having mild or moderate COPD was
associated with a 1.01 s (95% CI: 0.45–1.6, standardized
effect size: 0.26 (95% CI: 0.11–0.40)) longer time above
of what could be expected by purely additive influences
of both exposures individually. Participants with severe
or very severe COPD needed 1.15 s ((95% CI: 0.32–1.96),
standardized effect size 0.30 (95% CI: 0.08–0.43)) more
than what would be expected based on additive effect-
estimates.
Results from the sensitivity analyses, namely complete
case analysis of M2 (Additional file 1: Table S4) and
Table 3 Separate effects and effect of the COPD and HB product term on chair rise and word memorization
Time to complete Chair-riseb Number of words memorizedb
M1 d M2e M1d M2e
COPDa 1 vs. 0 0.17 (0.07 to 0.27) 0.11 (0.01 to 0.2) −0.08 (− 0.18 to 0.02) −0.04 (− 0.14 to 0.06)
2 vs. 0 0.31 (0.22 to 0.40) 0.23 (0.14 to 0.32) −0.15 (− 0.24 to − 0.07) −0.09 (− 0.18 to − 0.003)
3 vs. 0 0.58 (0.43 to 0.73) 0.46 (0.31 to − 0.60) −0.19 (− 0.34 to − 0.03) −0.10 (− 0.26 to 0.05)
4 vs. 0 0.74 (0.46 to 1.01) 0.64 (0.37 to 0.91) −0.12 (− 0.4 to 0.16) −0.04 (− 0.32 to 0.24)
HB-(g/dl)c Association between lower HB
level and time to complete chair rise
0.05 (0.03 to 0.06) 0.034 (0.02 to 0.05) −0.03 (− 0.04 to − 0.001) −0.02 (− 0.04 to − 0.001)
COPD + HB
(g/dl)
unit decrease in HB *COPD 1 vs. 0 0.1 (0.03 to 0.17) 0.1 (0.04 to 0.17) 0.11 (0.04 to 0.18) 0.11 (0.05 to 0.18)
Unit decrease in HB*COPD 2 vs. 0 0.04 (−0.02 to-0.11) 0.05 (−0.01 to 0.11) − 0.02 (− 0.08 to 0.04-) −0.03 (− 0.09 to 0.03)
Unit decrease in HB *COPD 3 vs. 0 0.08 (−0.01 to 0.18) 0.11 (0.02 to 0.2) −0.01(− 0.11 to 0.09)-) −0.02 (− 0.11 to 0.08)
Unit decrease in HB *COPD 4 vs. 0 0.36 (0.17 to 0.55) 0.36 (0.17 to 0.54) −0.03 (− 0.23 to 0.16) −0.04 (− 0.24 to 0.15)
aCOPD1 =mild; 2 =moderate; 3 = severe; 4 = very severe
bmodeled as the decrease per SD (SD− 1) in words memorized and time to complete chair raises
cHB was included as a continuous variable in g/dl
dadjustment model 1: sex and age, number of test repetitions; N = 8351 measurements; 5709 persons
emodel 2 additionally adjusts for blood pressure, myocardial infarction (MI), stroke, diabetes, total cholesterol, alcohol, depression grip strength and smoking,
imputed from complete data for M1 and available values for M2
*Product term
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weight corrected analyses of M1 and M2 shown in
Additional file 1: Table S5 were very similar to what was
described above.
With regard to the number of words memorized, no
supra-additive associations were observed (Table 2).
Continuous HB levels and motor function among COPD
categories
In further support of these results, our analyses in-
cluding the product term of the continuous HB level
and the categorical COPD variable indicated a stron-
ger association between HB levels and motor-
performance among participants with COPD. Per unit
(g/dl) lower HB level, the time needed to complete
the motor performance task was 0.39 s ((95% CI:
0.13–0.65), standardized effect size: 0.10 (95% CI: 0.03
to 0.17)) longer in individuals with mild COPD and
1.39 s ((95% CI: 0.65–2.13), standardized effect size
0.36 (95% CI: 0.17 to 0.55)) longer in participants
with very severe COPD (M1 results, Table 3).
The full range of these associations is illustrated in Fig. 2.
Here, the association of HB levels and motor or cognitive
performance in individuals with different levels of COPD
was only corrected for continuous HB levels, COPD and
the product term. Figure 2 shows that the slope of the
curve describing the association between HB levels and the
time needed to complete the motor-performance task was
steeper, illustrating the stronger association between HB
and motor performance in individuals with compared to
those without COPD. In other words if HB levels were
higher, on average persons with COPD were more likely to
have a motor-performance outcome similar to the average
of the healthy persons, or higher HB levels were associated
with a better functional outcome especially in persons with
COPD (Fig. 2).
The associations observed in M1 remained after add-
itional confounding adjustment but decreased by about
20–30% on average (Table 3). No such associations were
observed for the cognitive performance outcome (Table 3).
In sensitivity analyses, similar results were obtained for
complete case analysis of M2 (Additional file 1: Table
S6) and weight corrected analysis (Additional file 1:
Table S7). When using a broader definition for COPD
that allowed inclusion of more participants, the observed
associations decreased in magnitude (Additional file 1:
Table S8).
Discussion
In our study, we found that both COPD presence and
severity and low HB levels were associated with motor
performance in the older general population. With re-
gard to cognitive performance no relevant effects were
observed. Regarding motor performance, the associa-
tions persisted even after correction for confounding fac-
tors. Having both low HB levels and COPD was found
to have a supra-additive negative effect on the motor but
Fig. 2 Visualization of the association between HB and outcome measures in participants with different levels of COPD. Depicted is the mean
centered HB level against the estimated mean centered time to complete the motor task and the number of words memorized that were
normalized by dividing mean cantered values by the standard deviation (a and b). The association between HB level and cognitive as well as
motor-performance is shown for different groups of participants with COPD without confounder correction. a Shows that in participants with
COPD the time needed to perform the motor task increased more strongly with lower HB levels. In other words, in more severely affected
participants with COPD lower HB levels were more strongly associated with a longer time needed to complete the motor-performance task.
Overall, the association between a lower HB level and a worse motor function was stronger in participants with severe and very severe COPD
(bold dotted and straight lines 4 and 5) than in participants with mild and moderate COPD (lines 2 and 3). b Shows the association between HB
levels and the number of words memorized. Overall, within most of the COPD groups, with higher levels of HB, slightly more words were
memorized on average. However, no major differences between the different COPD groups were seen
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not on the cognitive performance task compared to each
exposure alone (Table 2). Furthermore, the association
between continuous HB levels and motor performance
differed between categories of COPD severity, with mod-
erately stronger positive associations observed between
HB levels and motor performance among participants
with COPD (Table 3, Fig. 2).
These results are of potentially of high clinical rele-
vance as both COPD and low HB are common in the
older population, as was also observed in our study
population. Maintaining HB levels might be important
for the preservation of motor performance in individuals
with COPD and thereby help to facilitate an active life-
style and reduce following adverse outcomes such as
falls and associated mortality.
The observed associations on motor outcomes
remained after full confounding adjustment in M2. Here
we also included depression and grip strength, which are
markers of general psychological as well as physical
health, which may confound the relationships under
study. However, we acknowledge that these variables
may also be mediators of the effects of HB or COPD on
the outcome measures, and correction in this case may
lead to over-adjustment in these models.
Current HB cutoffs and sex differences in defining
anemia might be questionable when used in the older
population [20]. HB levels generally decline with age
and current studies on HB levels show that especially
very high and very low levels in older persons are as-
sociated with increased hospitalization and mortality
[26]. Our results support a re-evaluation of the
current cutoffs used to define anemia (low HB) in
COPD patients. Defining more specific cut-offs, which
may include factors other than sex such as age, has
also previously been discussed [22]. Furthermore, HB
levels higher than the current cutoffs for anemia have
previously been reported to best predict survival in
COPD patients [27].
Our results indicate an effect of HB, COPD and their
combination on motor-performance but not on the de-
layed words recall task. This could suggest that the
motor effects may be attributable to an acute mismatch
between increased oxygen demand and supply during
physical activity in participants with COPD and not to a
general decline in cognitive motor control. This is sup-
ported by the fact that supra-additive effects were also
not seen when looking at immediate words recall
(Additional file 1: Table S9). We also studied balance, in
which cognitive motor control may also be a relevant
factor [28]. Only for mild and moderate COPD a trend
for small effect was seen in model 1 (standardized effect:
0.15, 95% CI: − 0.01 to 0.32) (Additional file 1: Table
S9). This effect however disappeared after full correction
in model 2, which further supports our hypothesis that
impairment seen in the five times sit to stand test was
mainly associated with acute oxygen deprivation during
the task and not with a more permanent loss of function
in motor control.
However, especially an acute mismatch in oxygen de-
mand and supply that did not yet lead to permanent
cognitive damage, might be reversible as the generally
most common causes of anemia –iron deficiency and in-
flammation are potentially treatable. Furthermore also
other causes such as for example vitamin D deficiency
or renal insufficiency might present plausible underlying
causes of anemia that can be treated. Further research
on anemia in COPD patients needed to be able to better
evaluate treatment options.
Limitations
Several limitations of our study should be considered.
First, our study includes a representative sample of the
English population aged 50 and older. Therefore, the
median age of our participants at baseline was 61, mean-
ing that many of the participants will first experience
stronger effects on cognitive decline later in life. There-
fore, results from similar analyses in an even older gen-
eral populations might reach different conclusions.
Some data were self-reported (e.g. history of alcohol
consumption, smoking, dyspnoea, stroke and myocardial
infarction) and this may have led to misclassification of
these confounding variables [29, 30]. However, the struc-
tured, repeated questionnaires were designed to reduce
the inaccuracy and reflect uncertainty in participant re-
call. Furthermore, with regard to cognitive function,
more extensive and specific neuropsychological testing
would have been preferred. For example, for relational
and non-relational material, different memory consolida-
tion rates have been suggested [31]. The test used in the
current study may not optimally reflect the capability of
our participants to remember facts relevant for their
daily living [31]. Despite the longitudinal character of
the ELSA study, general attrition of participants high
(Fig. 1). General attrition could be caused by participants
leaving their private residence and moving into nursing
homes. This could lead to an underrepresentation of
persons with very severe COPD, as they might be too se-
verely impaired to live at home and participate in the
ELSA study. However, the results from analyses of a
subset of participants for whom analytical weights were
given in an attempt to make the study population more
representative of the general UK population, led to simi-
lar results as our main analyses.
Conclusion
We set out to study the effect of HB levels and COPD, both
individually and in combination, on cognitive and motor-
performance in the older population. These relationships
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had yet to be evaluated in a population-based setting. Our
findings indicate that while cognitive performance as mea-
sured by a recall task does not seem to be affected, both
lower HB levels and more severe COPD were each associ-
ated with a worse motor-performance in an older general
population.
Moreover, individuals with low HB and COPD showed
a lower motor-performance than what would be ex-
pected based on the additive individual effects alone and
motor functional outcomes were more strongly
dependent on HB levels in individuals with COPD. Fu-
ture studies should investigate in more detail by which
mechanism and at which precise cutoff lower HB levels
in combination with COPD may cause a supra-additive
decline in motor-performance in older persons. We also
recommend a formal evaluation and optimization of
current HB cutoff levels, and assessment of whether
earlier treatment of low HB might prevent falls and asso-
ciated morbidity and mortality in the older population.
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